Search results for: Health Care Systems
Filter search results
OHE Study on Pharmaceutical R&D Costs Released
3 December 2012
…the long-term investments involved. The Office of Health Economics today released a comprehensive study of the cost of R&D for new medicines. How much it costs to research and develop…
New Findings: Public Attitudes Towards End-of-Life Treatment in England and Wales
7 December 2012
In 2009, the UK’s National Institute for Health and Clinical Excellence (NICE) issued supplementary advice that its Appraisal Committees are to consider when assessing treatments that extend life at the…
Spotlight on OHE: Value Based Pricing and New Technologies
31 December 2012
…also included how VBP might treat medicines with multiple indications of different “value”. Emerging Picture of Value Based Pricing from Office of Health Economics Adrian Towse was invited by…
Pharmacogenomics Testing: A Crucial Piece to Unlocking the Full Value of Medicines
5 June 2025
…do not deliver their intended therapeutic benefits for the individuals taking them—due to genetic variations. Despite the tremendous benefits that innovative medicines have brought to patients, health systems, and society,…
Cookie Policy
Cookies are small data files transferred to your computer’s hard drive through your web browser to enable our systems to recognise your browser and to provide us with details of…
Shalu Jain
29 June 2023
…of Health Research (DHR), MOHFW, New Delhi, India as Scientist-C and played a key role in establishing Health Technology Assessment in India (HTAIn), a unit within the health ministry to…
Charlotte Ashton-Khan
1 August 2022
…including the UN, WHO and World Economic Forum, Charlotte is interested in maximising the impact of health economic research to build alliances that create a thriving ecosystem benefiting health systems…
Nadine Henderson
26 September 2019
…environmental sustainability of the pharmaceutical industry and health systems. Her projects in this area include supporting the era of green pharmaceuticals in the UK and estimating the health and cost…
The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
1 July 2019
…Institute for Health Economics (IHE) in Sweden shows that health systems and societies in general (consumers) were able to appropriate most of the life-cycle value (surplus) generated by SGAs in…